Tag: CDMO

The business of making an antibody-drug conjugate (ADC) is becoming more complicated for reasons that have little to do with conjugation chemistry. Two US policy...

Mitigating Developability and Manufacturing Risks for Novel ADCs

Economy: Failure to Reshore Pharmaceutical Manufacturing: US Approved Drug Manufacturing Shifts to Europe as US Deal Volume Drops

Industry Report: Lotte's Strategic Rise as a Global CDMO Amid Industry Shifts

How CDMOs Can Unlock One-step, High-Yield and Homogeneous ADC Manufacturing

20-Hour Conjugation Bottlenecks – Confronting ADC Development Challenges with CDMOs

Abstract Bioconjugate therapeutics comprise a fast-growing class of drugs with applications in various disease areas. In the past years, particularly antibody-drug conjugates (ADCs) have undergone...

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer (and potentially other diseases). However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells.

At the 2022 World ADC Conference in San Diego, Stewart Mitchell, Executive Vice President and site head of Sterling Pharma Solutions' Deeside, U.K. facility, presented a case study on the development and GMP manufacture at the site.

Targeted therapies such as antibody-drug conjugates (ADC) have opened new ways in targeting diseases like cancer and hematological malignancies. High-potent active pharmaceutical ingredients, also...